A Phase 3 interventional study of Tenapanor in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-09.
Sponsored by Ardelyx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.
Among the 11 studies testing tenapanor in Constipation, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 5th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:
Ardelyx · Sites in United States
Ages 18–80
Cedar Valley Digestive Health Center · Sites in United States
Ages 50–89
Ardelyx · Sites in United States
Ages 6–18
By country, each count listing its studies:
tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8
First in 2011; this study’s year is marked. 1 started in 2016.
This study's enrollment of 312 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 186 across the 11 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 9 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies testing tenapanor in Constipation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing tenapanor in Constipation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III criteria. Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks) studies may be enrolled. Subjects will take tenapanor for approximately 52-55 weeks total based on previous protocol and this study.
During the treatment period of up to 39-weeks, subjects will return for study visits approximately every 13 weeks. Subjects will undergo safety assessments at these visits, which may include a physical exam, ECG, vital signs, and clinical labs. Adverse events and concomitant medications will be recorded. Medication compliance will be monitored and the subjects will be given additional study drug as appropriate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenapanor, 50 mg BID (100 mg total)
Drug: Tenapanor
Also known as: RDX5791, AZD1722
Adverse Events in >2% Patients
Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams
Time frame: 52-55 weeks
| Milestone | 50mg BID |
|---|---|
| Started | 312 |
| Completed | 262 |
| Not completed | 50 |
Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams
| participants | 50mg BID |
|---|---|
| Diarrhea | 33 |
| Flatulence | 7 |
| Upper Respiratory Tract Infection | 7 |
| Headache | 11 |
Collected over This was an extension study that ran for up to 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50mg BID | 0/312 (0%) | 3/312 (1%) | 33/312 (10.6%) |
| Event | 50mg BID |
|---|---|
| LeukocytosisBlood and lymphatic system disorders | 1/312 |
| Rib FractureInjury, poisoning and procedural complications | 1/312 |
| EndometriosisReproductive system and breast disorders | 1/312 |
| Event | 50mg BID |
|---|---|
| DiarrheaGastrointestinal disorders | 33/312 |
| Age, Continuous(years) | 50mg BID |
|---|---|
| Mean | 49.5 ± 13.15 |
| Sex: Female, Male(Participants) | 50mg BID |
|---|---|
| Female | 255 |
| Male | 57 |
| Ethnicity (NIH/OMB)(Participants) | 50mg BID |
|---|---|
| Hispanic or Latino | 130 |
| Not Hispanic or Latino | 182 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 50mg BID |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 89 |
| White | 217 |
| More than one race | 2 |
| Unknown or Not Reported | 2 |
| Body Mass Index (BMI)(kg/m^2) | 50mg BID |
|---|---|
| Mean | 29.98 ± 6.707 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2016, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2020, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor